Please wait while we load the requested 10-K report or click the link below:
2301 Crown CourtIrving, Texas 75038
For Further Information:
For Immediate Release
Steve Brown, CFO
Royal BodyCare Reports Annual Results
Irving, Texas (March 9, 2005)Royal BodyCare, Inc. (ROBE OTC:BB) today reported an increase in net sales to $19,361,000 and an increase in net earnings to $592,000, or $0.03 per share, in the year ended December 31, 2005, compared to net sales of $18,266,000 and net earnings of $537,000, or $0.03 per share, in the prior year.
At December 31, 2005, the Company reported backlog of $2,400,000 compared to backlog at the end of the prior year of $2,300,000.
Clinton Howard, CEO said, We were pleased to be able to increase earnings even though we expensed approximately $180,000 in 2005 preparing to open a new wholly owned subsidiary, RBC Life Sciences Korea Co., Ltd., which opened in the first quarter of 2006.
We changed the names of our operating entities in the U.S. and Canada to incorporate the RBC Life Sciences brand. In addition the Board of Directors will recommend that the shareholders approve changing the name of the parent company from Royal BodyCare, Inc. to RBC Life Sciences, Inc. at the next annual shareholders meeting, scheduled for June 1, 2006.
RBC began significant sales to new licensees in France, South Africa, and Saudi Arabia. In addition, the Companys largest licensee expanded sales of RBC products into several countries in Eastern Europe in accordance with the terms of the license agreement.
RBC formulates, manufactures, and markets a research-based line of quality-controlled nutritional supplements and skin care products in compliance with GMP standards. We sell directly through independent distributors in North America, and through licensees in over 20 other countries, from our Las Colinas headquarters in Irving, Texas, and from branch offices in Vancouver, BC, Canada and Seoul Korea.
MPM Medical, Inc.
MPM Medical, a wholly owned subsidiary of RBC, develops and markets a proprietary line of research-based wound care products sold over-the-counter and by prescription through drug wholesalers, hospitals, clinics, cancer centers and nursing homes.
The following information was filed by Rbc Life Sciences, Inc. (RBCL) on Friday, March 10, 2006 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Rbc Life Sciences, Inc.'s financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Rbc Life Sciences, Inc..